Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 884-888

  Wang, Wei ^a   Jiang, Haowen ^a   Zhu, Hechen ^b   Zhang, Hu ^a   Gong, Jian ^a   Zhang, Limin ^a   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Bladder carcinoma; High mobility group box

Indexed keywords

CD34 ANTIGEN; HIGH MOBILITY GROUP B PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; MESSENGER RNA; VASCULOTROPIN;

AGED; ANGIOGENESIS; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84872712322     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1091     Document Type: Article

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Ghoneim MA, Abdel-Latif M, El-Mekresh M, et al: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 180: 121-127, 2008.
3. Vishnu P, Mathew J and Tan WW: Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 4: 97-113, 2011.
4. van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11: 91-99, 2008.
5. Zhang J, McCauley MJ, Maher LJ III, et al: Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 37: 1107-1114, 2009.
6. Stros M, Polanská E, Struncová S and Pospísilová S: HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomeraseIIalpha. Nucleic Acids Res 37: 2070-2086, 2009.
7. Krynetskaia NF, Phadke MS, Jadhav SH and KrynetskiyEY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 8: 864-872, 2009.
8. Balani P, Boulaire J, Zhao Y, et al: High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol Ther 17: 1003-1011, 2009.
9. Naglova H and Bucova M: HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 113: 163-171, 2012.
10. Franklin S, Chen H, Mitchell-Jordan S, et al: Quantitative analysis of the chromatin proteome in disease reveals remodeling principles and identifies high mobility group protein b2 as a regulator of hypertrophic growth. Mol Cell Proteomics 11: M111.014258, 2012.
11. Dong Xda E, Ito N, Lotze MT, et al: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30: 596-606, 2007.
12. Yao X, Zhao G, Yang H, et al: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 136: 677-684, 2010.
13. Shen X, Hong L, Sun H, et al: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 22: 535-539, 2009.
14. Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258, 2010.
15. Sharma A, Ray R and Rajeswari MR: Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 26: 843-851, 2008.
16. Gnanasekar M, Thirugnanam S and Ramaswamy K: Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34: 425-431, 2009.
17. Song B, Song WG, Li ZJ, et al: Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct 30: 11-17, 2012.
18. Rhodes DR, Yu J, Shanker K, et al: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309-9314, 2004.
19. Jiao Y, Wang HC and Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28: 1957-1967, 2007.
20. Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
21. Sitohy B, Nagy J and Dvorak H: Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72: 1909-1914, 2012.
22. Ajili F, Kacem M, Tounsi H, et al: Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 36: 336-342, 2012.
23. Deniz H, Karakök M, Yagci F and Güldür ME: Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 42: 103-107, 2012.
24. Yang GL, Zhang LH, Bo JJ, et al: Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 106: 57-61, 2012.
25. Tang D, Kang R, Cheh CW, et al: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29: 5299-5310, 2010.
26. Todorova J and Pasheva E: High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 3: 214-218, 2012.
27. Pusterla T, de Marchis F, Palumbo R and Bianchi ME: High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 42: 308-310, 2009.
28. Le XF, Lammayot A, Gold D, et al: Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280: 2092-2104, 2005.
29. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene: Mar 5, 2012 (Epub ahead of print). doi: 10.1038/onc.2012.49.
30. Sachdev U, Cui X, Hong G, et al: High mobility group box 1 promotes endothelial cell angiogenic behavior invitro and improves muscle perfusion invivo in response to ischemic injury. J Vasc Surg 55: 180-191, 2012.
31. Urquidi V, Goodison S, Kim J, et al: Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 79: 1185. e1-6, 2012.
32. Chavakis E, Hain A, Vinci M, et al: High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212, 2007.